Todd Tushla | VP, IR |
Kevin Gorman | CEO |
Matt Abernethy | CFO |
Eiry Roberts | Chief Medical Officer |
Eric Benevich | Chief Commercial Officer |
Kyle Gano | Chief Business Development and Strategy Officer |
Paul Matteis | Stifel |
Phil Nadeau | Cowen and Company |
Brian Abrahams | RBC |
David Amsellem | Piper Sandler |
Paul Choi | Goldman Sachs |
Marc Goodman | SVB Leerink |
Biren Amin | Jefferies |
Charles Duncan | Cantor Fitzgerald |
Jay Olson | Oppenheimer & Co. |
Good day, everyone, and welcome to today’s Neurocrine Biosciences Reports Second Quarter 2020 Results. At this time, all participants are in a listen-only mode. Later, you’ll have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] I’ll be standing by if you should need audio assistance. And it is now my pleasure to turn today’s conference over to Todd Tushla, VP of Investor Relations.